Evofem Biosciences

196 articles about Evofem Biosciences

• Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

  5/22/2018

  The shares and pre-funded warrants are being sold at a public offering price of $4.69 per share and $4.68 per pre-funded warrant

• 

  Recent Movement in Anti-Infectives Point to a Growing Market

  5/7/2018

  On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.

• Evofem Biosciences Announces Proposed Public Offering of Common Stock

  4/24/2018

  Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offering of $40.0 million of its common stock

• Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

  2/21/2018

  Evofem Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® vaginal gel for the prevention of urogenital chlamydia in women.

• 

  FDA Grants Evofem Biosciences’ Amphora Fast Track Designation

  2/21/2018

  The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.

• Evofem Biosciences Completes Enrollment of Phase III Contraceptive Trial of Amphora Ahead of Schedule

  2/15/2018

  Trial data is expected in the first quarter of 2019.

• Evofem Biosciences Announces First Patient Enrolled in Phase Ib/III STI Trial of Amphora and Expects Phase III Contraceptive Clinical Trial Data First Quarter 2019

  1/23/2018

  Evofem Biosciences today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.

• Evofem Announces Closing of Merger With Neothetics

  1/18/2018

  The merged company will operate as Evofem Biosciences and will focus on the continued development and commercialization of women's healthcare products.

• Neothetics and Evofem Biosciences Announce Merger Agreement to Create Women’s Health Company

  10/17/2017

  The merger will position the combined company with an opportunity to become a leading women's health company that develops and commercializes novel products.

• Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy

  7/28/2017

• Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph

  8/17/2016

• Evofem Secures $25.0 Million In Series D Funding

  8/4/2016

• Evofem CEO, Saundra Pelletier, To Address The Cavendish Global Health Impact Forum At BIOCOM On Innovations In Reproductive Health Care Around The Globe

  6/16/2016

• Evofem And WomanCare Global To Attend Women Deliver 2016

  5/16/2016

• Evofem Files IND For Evaluation Of Prevention Of Recurrence Of Bacterial Vaginosis

  3/31/2016

• Evofem And DKT To Develop Coated Condom

  2/9/2016